| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3274098 | Médecine des Maladies Métaboliques | 2016 | 4 Pages |
Abstract
Regarding renal risk, observational studies suggest a possible deleterious effect of SU while specific medications were not studied. Conversely, the ADVANCE trial is positive for the hard renal outcome (renal replacement therapy) suggesting a beneficial impact of gliclazide LM. Insulin has not been widely studied but data still suggest a neutral effect. The level of evidence regarding SU/glinides and insulin remain rather poor.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
S. Hadjadj, E. Feigerlova, M. Fraty, X. Piguel, F. Torremocha, R. Maréchaud,